Your browser doesn't support javascript.
loading
Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.
Wirtz, Heidi S; Sheer, Richard; Honarpour, Narimon; Casebeer, Adrianne W; Simmons, Jeff D; Kurtz, Christopher E; Pasquale, Margaret K; Globe, Gary.
Afiliación
  • Wirtz HS; Amgen Inc. Thousand Oaks CA.
  • Sheer R; Humana Healthcare Research Inc. Louisville KY.
  • Honarpour N; Amgen Inc. Thousand Oaks CA.
  • Casebeer AW; Humana Healthcare Research Inc. Louisville KY.
  • Simmons JD; Humana Inc. Louisville KY.
  • Kurtz CE; Amgen Inc. Thousand Oaks CA.
  • Pasquale MK; Humana Healthcare Research Inc. Louisville KY.
  • Globe G; Amgen Inc. Thousand Oaks CA.
J Am Heart Assoc ; 9(16): e015042, 2020 08 18.
Article en En | MEDLINE | ID: mdl-32805181
Background Patients hospitalized with heart failure (HF) with reduced ejection fraction have high risk of rehospitalization or death. Despite guideline recommendations based on high-quality evidence, a substantial proportion of patients with HF with reduced ejection fraction receive suboptimal care and/or do not comply with optimal care following hospitalization. Methods and Results This retrospective observational study identified 17 106 patients with HF with reduced ejection fraction with an incident HF-related hospitalization using the Humana Medicare Advantage database (2008-2016). HF medication classes (beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, or mineralocorticoid receptor antagonists) received in the year after hospitalization were recorded, and categorized by treatment intensity (ie, number of concomitant medication classes received: none [23% of patients; n=3987], monotherapy [22%; n=3777], dual therapy [41%; n=7056], or triple therapy [13%; n=2286]). Compared with no medication, risk of primary outcome (composite of death or rehospitalization) was significantly reduced (hazard ratio [95% CI]) with monotherapy (0.68 [0.64-0.71]), dual therapy (0.56 [0.53-0.59]), and triple therapy (0.45 [0.41-0.50]). Nearly half (46%) of patients who received post-discharge medication had no dose escalation. Overall, 59% of patients had follow-up with a primary care physician within 14 days of discharge, and 23% had follow-up with a cardiologist. Conclusions In real-world clinical practice, increasing treatment intensity reduced risk of death and rehospitalization among patients hospitalized for HF, though the use of guideline-recommended dual and triple HF therapy remained low. There are opportunities to improve post-discharge medical management for patients with HF with reduced ejection fraction such as optimizing dose titration and improving post-discharge follow-up with providers.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cuidados Posteriores / Insuficiencia Cardíaca Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: J Am Heart Assoc Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cuidados Posteriores / Insuficiencia Cardíaca Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: J Am Heart Assoc Año: 2020 Tipo del documento: Article